Physician profile
Henry H Dohn
NPI 1407857956
$65,973.02
in general payments reported to CMS, 2019-2025
26 companies · $1,252 in 2025
The $1,252 reported for 2025 was more than what 84% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $6,485 · 2021: $5,272 · 2022: $19K · 2023: $11K · 2024: $2,389 · 2025: $1,252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,800 · Food and Beverage: $2,992 · Travel and Lodging: $1,663 · Education: $54.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,800.00 |
| Food and Beverage | $2,991.88 |
| Travel and Lodging | $1,662.64 |
| Education | $54.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $26,091.39 | 2021-2025 | Vraylar |
| Allergan, INC. | $19,046.03 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $16,433.51 | 2019-2025 | Ingrezza |
| Jazz Pharmaceuticals INC. | $1,303.04 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $805.61 | 2019-2025 | Rexulti, Nuedexta |
| Axsome Therapeutics, INC. | $453.90 | 2022-2025 | Sunosi, Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $296.10 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $253.94 | 2019-2025 | Spravato |
| Lundbeck LLC | $214.15 | 2022-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $182.44 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $180.13 | 2023-2025 | Quviviq, Quviviq |
| Vanda Pharmaceuticals INC. | $112.07 | 2025 | Fanapt |
| Almatica Pharma LLC | $84.39 | 2022-2024 | Loreev Xr |
| Neos Therapeutics, LP | $74.93 | 2022-2025 | Adzenys Xr-Odt, Exxua |
| Corium, LLC | $69.85 | 2022-2025 | Azstarys |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $59.15 | 2022-2024 | Qelbree |
| Alkermes, INC. | $50.49 | 2022-2023 | Aristada, Lybalvi |
| Shire North American Group INC | $45.58 | 2019 | |
| Avanir Pharmaceuticals, INC. | $42.26 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.34 | 2022 | |
| Ironshore Pharmaceuticals INC. | $31.33 | 2019-2023 | Jornay Pm |
| Bausch Health US, LLC | $25.63 | 2022 | |
| Tonix Medicines, INC. | $23.60 | 2025 | Tonmya |
| Neuronetics, INC. | $21.91 | 2019 | |
| Tris Pharma INC | $17.22 | 2023 | Dyanavel Xr |
| Teva Pharmaceuticals USA, INC. | $17.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Dohn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.